Sugi Predict

Sugi Predict / Compounds / Gluconolactone

Gluconolactone

Gluconolactone

SCHEMBL10221981

O=C1OC(CO)[C@@H](O)C(O)C1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 1.00
▸ GBA1 P04062 2/20 1.00
▸ HIF1A Q16665 2/20 0.47
▸ MANBA O00462 2/20 0.47
▸ IDUA P35475 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ GUSB P08236 1/20 0.47
▸ CYP2C19 P33261 1/20 0.42
▸ DNMT1 P26358 1/20 0.38
▸ CTDSP1 Q9GZU7 1/20 0.38
▸ OGA O60502 1/20 0.38
▸ GAA P10253 1/20 0.37
▸ PYGB P11216 2/20 0.37
▸ PYGL P06737 1/20 0.37
▸ PYGM P11217 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gluconolactone SCHEMBL18465607 1.00 LMNA (1.00) LMNAGBA1HIF1AMANBAIDUA
Gluconolactone SCHEMBL333412 1.00 LMNA (1.00) LMNAGBA1HIF1AMANBAIDUA
Gluconolactone SCHEMBL2466472 1.00 LMNA (1.00) LMNAGBA1HIF1AMANBAIDUA
Gluconolactone SCHEMBL7148519 1.00 LMNA (1.00) LMNAGBA1HIF1AMANBAIDUA
Gluconolactone SCHEMBL17068350 1.00 LMNA (1.00) LMNAGBA1HIF1AMANBAIDUA
Gluconolactone SCHEMBL15631270 1.00 LMNA (1.00) LMNAGBA1HIF1AMANBAIDUA
Gluconolactone SCHEMBL24637666 1.00 LMNA (1.00) LMNAGBA1HIF1AMANBAIDUA
Gluconolactone SCHEMBL15631261 1.00 LMNA (1.00) LMNAGBA1HIF1AMANBAIDUA
Gluconolactone SCHEMBL15631260 1.00 LMNA (1.00) LMNAGBA1HIF1AMANBAIDUA
Gluconolactone SCHEMBL2464302 1.00 LMNA (1.00) LMNAGBA1HIF1AMANBAIDUA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399754-A1 CLEANING COMPOSITION WITH MOLYBDENUM ETCHING INHIBITOR ENTEGRIS, INC. 2023-12-14 — — US disclosed
WO-2023115798-A1 METHOD FOR SYNTHESIZING RARE SUGAR NUCLEOTIDE FROM UDP-GLCNAC 中国科学院上海药物研究所 2023-06-29 — — WO disclosed
US-20230121990-A1 COMPOSITIONS AND METHODS FOR PRODUCTION OF GLUCOSE OXIDATION PRODUCTS SOLUGEN, INC. (US) 2023-04-20 — — US disclosed
US-20220372421-A1 KIT AND METHOD FOR PREPARATION OF DIGESTIBLE SPHEROID STABILIZING HYDROGELS CORNING INCORPORATED 2022-11-24 — — US disclosed
US-10252962-B2 Process for production of D-Sorbitol DSM IP ASSETS B.V. (NL) 2019-04-09 — — US disclosed
US-20180201558-A1 PROCESS FOR PRODUCTION OF D-SORBITOL DSM IP ASSETS B.V. (NL) 2018-07-19 — — US disclosed
US-20180110872-A1 MULTI-ARM LINKERS FOR CONSTRUCTING PHARMACEUTICAL MOLECULES Immunwork Inc. (TW) 2018-04-26 — — US disclosed
US-9695193-B2 Inhibitors of Plasmodium falciparum equilibrative nucleoside transporter type I as anti-parasitic compounds THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-07-04 — — US disclosed
US-9138484-B2 Conjugates containing hydrophilic spacer linkers ENDOCYTE, INC. (US) 2015-09-22 — — US disclosed
US-20120022245-A1 FOLATE TARGETING OF NUCLEOTIDES PURDUE RESEARCH FOUNDATION (US) 2012-01-26 — — US disclosed
US-20110212906-A1 C-LINKED GLUCURONIDE OF N-(4-HYDROXYBENZYL) RETINONE, ANALOGS THEREOF, AND METHODS OF USING THE SAME TO INHIBIT NEOPLASTIC CELL GROWTH THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION 2011-09-01 — — US disclosed
US-7915318-B2 Aqueous ROMP-based monolith materials and methods for making GENERAL ELECTRIC COMPANY (US) 2011-03-29 — — US disclosed
US-7915318-B2 Aqueous ROMP-based monolith materials and methods for making GENERAL ELECTRIC COMPANY (US) 2011-03-29 — — US disclosed
US-20100323973-A1 CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS ENDOCTYE, INC. 2010-12-23 — — US disclosed
WO-2010045584-A1 FOLATE TARGETING OF NUCLEOTIDES ENDOCYTE, INC. (US) 2010-04-22 — — WO disclosed
US-20100063200-A1 AQUEOUS ROMP-BASED MONOLITH MATERIALS AND METHODS FOR MAKING GENERAL ELECTRIC COMPANY (US) 2010-03-11 — — US disclosed
US-20100063200-A1 AQUEOUS ROMP-BASED MONOLITH MATERIALS AND METHODS FOR MAKING GENERAL ELECTRIC COMPANY (US) 2010-03-11 — — US disclosed
US-7528114-B2 C-linked glucuronide of N-(4-hydroxybenzyl) retinone, analogs thereof, and method of using the same to inhibit neoplastic cell growth WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2009-05-05 — — US disclosed
US-20090112002-A1 PROCESS FOR PREPARATION OF ALDONIC ACIDS AND DERIVATIVES THEREOF APTALIS PHARMA CANADA INC. (CA) 2009-04-30 — — US disclosed
WO-2008053206-A2 PROCESS FOR PREPARATION OF ALDONIC ACIDS AND DERIVATIVES THEREOF C.B. FLEET COMPANY, INC. (US) 2008-05-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022245-A1 FOLATE TARGETING OF NUCLEOTIDES FOLR1, FOLR2, DHFR LMNA 2529/4885GBA1 2393/4885HIF1A 2019/4885
US-10252962-B2 Process for production of D-Sorbitol SORD, ALDOA, DCXR LMNA 3705/4885GBA1 853/4885HIF1A 2667/4885
US-20180110872-A1 MULTI-ARM LINKERS FOR CONSTRUCTING PHARMACEUTICAL MOLECULES HAVCR2, PLK1, ILK LMNA 2926/4885GBA1 282/4885HIF1A 4301/4885
US-20110212906-A1 C-LINKED GLUCURONIDE OF N-(4-HYDROXYBENZYL) RETINONE, ANALOGS THEREOF, AND METHODS OF USING THE SAME TO INHIBIT NEOPLASTIC CELL GROWTH ALDH1A2, UGT2B17, UGT2B7 LMNA 1609/4885GBA1 917/4885HIF1A 1744/4885
US-20180201558-A1 PROCESS FOR PRODUCTION OF D-SORBITOL SORD, ALDOA, DCXR LMNA 3705/4885GBA1 853/4885HIF1A 2667/4885
US-20100323973-A1 CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS CD44, HAVCR2, HCAR1 LMNA 903/4885GBA1 309/4885HIF1A 411/4885
US-20090112002-A1 PROCESS FOR PREPARATION OF ALDONIC ACIDS AND DERIVATIVES THEREOF ALDOA, ALG1, DERA LMNA 930/4885GBA1 99/4885HIF1A 1508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.